Management of Prostatodynia in Younger Patients With Non-ablative Erbium:YAG Intraurethral Laser

• Status: Completed
• Trial end date: 2018-12-31
• Target enrollment: 0
• Participant gender: Male

Summary

This prospective study aimed to compare the clinical outcomes between the use of the erbium:

YAG (Er:YAG) laser, intraurethrally administered in long non-ablative SMOOTH™ train of pulses applied at the level of the male prostatic urethra, to the use of the pharmacological treatment of oral tadalafil for the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS). The results show that both treatments are effective in alleviating symptoms of CP/CPPS. The non-ablative Er:YAG SMOOTHTM laser seems to be a promising treatment for this widely spread condition. More studies are needed to confirm its safety and efficacy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Adrian Gaspar
• Treatments: Tadalafil

Criteria

Inclusion Criteria:

• clinical diagnosis of chronic prostatitis/chronic pelvic pain syndrome with characteristic symptoms of perineal pain and urinary symptoms of dysuria and urinary frequency;

• negative urine culture after prostatic massage; prostatic volume less than 50 cc in prostatic ultrasound;

• obstructive uroflowmetric pattern with a Q-max value between 10 and 15 ml/sec

Exclusion Criteria:

• age over 50 years

• current or recent (last 6 months) pharmacological or other therapies of CP/CPPS